Research progress in prevention and cure of glucagon-like peptide-1 receptor agonists-1 receptor agonists for diabetic retinopathy
Diabetic retinopathy(DR)is one of the most frequent complications of diabetes(T2DM),which is the main eye disease causing blindness in adults in recent years.At present,glucagon-like peptide-1 receptor agonists(GLP-1RA)have become the main drugs used in the treatment of diabetes due to its superior hypoglycemic,lipid-lowering,hypertensive and cardiovascular effects.A large number of studies have shown that GLP-1RA drugs can protect retinal microvascular and optic nerves in the treatment of diabetes through various ways,but some studies have found that GLP-1RA drugs represented by semaglutide may lead to the progress of DR.Therefore,GLP-1RA should be used cautiously for patients who with severe non-proliferative DR or proliferative DR.Regardless of whether T2DM patients are complicated with DR,the fundus retinal condition should be monitored regularly after the use of GLP-1RA drugs,and timely countermeasures should be taken when DR occurs and develops.The benefits of GLP-1RA used by diabetes patients are obvious to all,and scientific and rational drug use can prevent the occurrence and progress of DR,which can better benefit DR Patients.